Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $4.01, but opened at $3.84. Evotec shares last traded at $3.94, with a volume of 25,256 shares traded.
Analysts Set New Price Targets
EVO has been the subject of a number of recent research reports. Royal Bank of Canada reissued an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Evotec presently has an average rating of "Hold" and a consensus target price of $5.93.
Check Out Our Latest Stock Report on Evotec
Evotec Stock Up 17.4%
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The business's 50-day simple moving average is $3.72 and its 200-day simple moving average is $4.18.
Institutional Investors Weigh In On Evotec
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. DCF Advisers LLC grew its stake in shares of Evotec by 227.0% during the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock worth $2,510,000 after purchasing an additional 521,708 shares during the period. ABC Arbitrage SA acquired a new stake in shares of Evotec during the 1st quarter worth approximately $260,000. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec during the 4th quarter worth approximately $166,000. Bank of America Corp DE grew its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after purchasing an additional 9,289 shares during the period. Finally, CSS LLC IL acquired a new stake in shares of Evotec during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
